Clinical pharmacology of anti-angiogenic drugs in oncology. (November 2017)

• Record Type: Journal Article
• Authors: Gougis, P.; Wassermann, J.; Spano, J.P.; Keynan, N.; Funck-Brentano, C.; Salem, J.E.
• Is Part Of: Critical reviews in oncology/hematology. Volume 119(2017)
• Page Start: 75
• Page End: 93
• Publication Date: 2017-11
• Subjects: Angiogenesis inhibitors -- Neovascularization -- Pharmacokinetics -- Pharmacodynamics -- Protein kinase inhibitors -- Monoclonal antibodies; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2017.08.010
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two decades. Two types of anti-angiogenics have been approved: monoclonal antibodies and derivatives, which are injected and target the extracellular part of a receptor, and protein kinase inhibitors, which are orally taken small molecules targeting the intra-cellular Adenosine Triphosphate –pocket of different kinases. They have become an important part of some tumors' treatment, both in monotherapy or in combination. In this review, we discuss the key pharmacological concepts and the major pitfalls of anti-angiogenic prescriptions. We also review the pharmacokinetic and pharmacodynamics profile of all approved anti-angiogenic protein kinase inhibitors and the potential role of surrogate markers and of therapeutic drug monitoring.